How Low Can We Go? Metastatic Breast Cancer Enters a New Era of HER2 Classification - OncLive

How Low Can We Go? Metastatic Breast Cancer Enters a New Era of HER2 Classification - OncLive
Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of exp…
Data from DESTINY-Breast04 (NCT03734029) presented at the 2022 ASCO Annual Meeting thrust the topic of defining HER2-low metastatic breast cancer into the spotlight; however, the continuum of HER2 ex… [+14518 chars] Read More



Related Stories

See All